CN102210836A - Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer - Google Patents
Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer Download PDFInfo
- Publication number
- CN102210836A CN102210836A CN2010101412123A CN201010141212A CN102210836A CN 102210836 A CN102210836 A CN 102210836A CN 2010101412123 A CN2010101412123 A CN 2010101412123A CN 201010141212 A CN201010141212 A CN 201010141212A CN 102210836 A CN102210836 A CN 102210836A
- Authority
- CN
- China
- Prior art keywords
- herba
- gained
- radix
- ligustri lucidi
- fructus ligustri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a Chinese medicinal composition in preparation of a medicine for treating stomach cancer. The Chinese medicinal composition is prepared from Chinese medicines such as astragalus, glossy privet fruit and the like. The Chinese medicinal composition has the effects of tonifying qi and yin, invigorating spleen and nourishing kidney, and eliminating stagnation and activating meridians and directly reaches lesion sites. Clinical use proves that the Chinese medicinal composition has a relatively good curative effect. The Chinese medicinal composition has a reasonable formula, is free from adverse effect and can be taken for a long time.
Description
Technical field
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, relate to the application of a kind of Chinese medicine composition in preparation treatment gastric cancer medicine, belong to the Chinese medicine application.
Background technology
Gastric cancer is one of modal malignant tumor of China, and its M ﹠ M all occupies the malignant tumor first place, because the early gastric cancer atypical symptom, majority has belonged to progressive stage when making a definite diagnosis, lymphatic metastasis has perhaps taken place, or even the far-end transfer, or old, lost the surgical engine meeting, therefore the treatment of main inner section, however gastric cancer to present existing chemotherapeutics relative insensitivity, its curative effect is limited, and old patients with gastric cancer is older, and the body tolerance is poor.Therefore, Chinese medicine seems particularly important.
The tumor patient cellular immunity is low, especially progressive stage tumor, studies show that, the antitumor immunity of organism reaction is based on cellular immunization, the t lymphocyte subset group regulates and control the immunne response of body and keeps immune stable playing an important role, and cd4 cell is a dominant response cell in the immunne response, and cd8 cell can produce cell-mediated cytotoxicity to target cell, simultaneously cd4 cell is had the modulability inhibitory action, CD4/CD8 ratio can react the body cell immune functional state.Natural killer cell (NK) is the main component that immunity of organism monitors, has cellular immunization and immunoregulatory effect, and tumor cell is had the non-limiting cytotoxicity of MHC, is regarded as body antineoplastic the first line of defence.
The mechanism of gastric cancer is very complicated, not only relates to the variation of multiple oncogene, antioncogene, and some cytokines also play a role in occurrence and development of gastric carcinomas.Although the model of action difference of these genes, cytokine pair cell, action pathway and site of action are different, and final result all will cause the malignant proliferation of cell.Proliferating cell nuclear antigen (proliferating cellnuclear antigen, PCNA) be the cofactor of archaeal dna polymerase δ, not only in dna replication dna, play a key effect, and all must could cause the synthetic of DNA through the participation of PCNA from the proliferation signal inside and outside the cell.Numerous studies show that, PCNA has highly expression in nearly all tumor tissues, and PCNA is almost 100% in the positive expression rate of gastric cancer.
The activation of proto-oncogene, the sudden change of antioncogene are the important molecule bases that tumor forms.The p53 gene is to find so far and the highest gene of human tumor dependency, generally believe that now p53 is an antioncogene, p53 producer sudden change or with other protein-interactings, cause the disappearance or the change of self normal function, cell cycle loses normal regulation and control, the hyperplasia that becomes is also more responsive to the change of other gene, develops into genomic instability and non-multiple state, and then develops into cancer.
The present invention is the improvement invention of carrying out on No. 200410012347.4 basis, quotes in full the content of this patent document record at this.The application of unexposed this Chinese medicine composition of above-mentioned patent in treatment gastric cancer medicine.
Summary of the invention
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, relate to the application of a kind of Chinese medicine composition in preparation treatment gastric cancer medicine.
The objective of the invention is to: be the clinical medicine that effective treatment gastric cancer that a kind of medical material compatibility is reasonable, therapeutic effect is desirable, have no side effect is provided.
Preferably, the present invention also provides the application of this Chinese medicine composition in the medicine of preparation enhancing patients with gastric cancer t lymphocyte subset group and natural killer cell activity.
Also preferably, the present invention also provides the application of this Chinese medicine composition in the medicine of preparation inhibition patients with gastric cancer cancer proliferating cell nuclear antigen and saltant P53 protein expression.
Chinese medicine of the present invention all can be concocted according to " national Chinese medicine processing standard " or " Chinese medicine voluminous dictionary ".Medicine of the present invention is to be made by the crude drug that comprises following weight portion ratio:
Radix Astragali 120-360 Fructus Ligustri Lucidi 100-300 Radix Ginseng 30-95 Ganoderma 30-95
Rhizoma Curcumae 65-195 Rhizoma Atractylodis Macrocephalae 30-90 Herba Scutellariae Barbatae 65-195 Herb Gynostemmae Pentaphylli 120-360
Poria 30-95 Endothelium Corneum Gigeriae Galli 15-45 Herba Duchesneae Indicae 65-195 Herba Solani Lyrati 65-195
Herba Artemisiae Scopariae 65-195 Radix Cynanchi Paniculati 65-195 Eupolyphaga Seu Steleophaga 10-30 Herba Hedyotidis Diffusae 65-195.
Preferably, this Chinese medicine composition is made by following bulk drugs:
The Radix Astragali 120 Fructus Ligustri Lucidi 300 Radix Ginsengs 30 Ganodermas 95 Rhizoma Curcumae 65
The Rhizoma Atractylodis Macrocephalae 90 Herba Scutellariae Barbataes 65 Herb Gynostemmae Pentaphylli 360 Poria 30 Endothelium Corneum Gigeriae Galli 45
Herba Duchesneae Indicae 65 Herba Solani Lyratis 195 Herba Artemisiae Scopariaes 65 Radix Cynanchi Paniculatis 195
Eupolyphaga Seu Steleophaga 10 Herba Hedyotidis Diffusaes 195.
Or
The Radix Astragali 360 Fructus Ligustri Lucidi 100 Radix Ginsengs 95 Ganodermas 30 Rhizoma Curcumae 195
The Rhizoma Atractylodis Macrocephalae 30 Herba Scutellariae Barbataes 195 Herb Gynostemmae Pentaphylli 120 Poria 95 Endothelium Corneum Gigeriae Galli 15
Herba Duchesneae Indicae 195 Herba Solani Lyratis 65 Herba Artemisiae Scopariaes 195 Radix Cynanchi Paniculatis 65
Eupolyphaga Seu Steleophaga 30 Herba Hedyotidis Diffusaes 65.
Or
The Radix Astragali 250 Fructus Ligustri Lucidi 200 Radix Ginsengs 65 Ganodermas 65 Rhizoma Curcumae 132
The Rhizoma Atractylodis Macrocephalae 64 Herba Scutellariae Barbataes 128 Herb Gynostemmae Pentaphylli 256 Poria 65 Endothelium Corneum Gigeriae Galli 30
Herba Duchesneae Indicae 128 Herba Solani Lyratis 128 Herba Artemisiae Scopariaes 128 Radix Cynanchi Paniculatis 128
Herba Hedyotidis Diffusae 128 Eupolyphaga Seu Steleophagas 20.
Preferably, in the raw materials used medicine of described Chinese medicine composition, the Rhizoma Atractylodis Macrocephalae is a Rhizoma Atractylodis Macrocephalae (parched).
The present invention also provides the active component of described Chinese medicine composition to be made by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Fructus Ligustri Lucidi, people participate in 6-10 and doubly measure the 50-90% ethanol extraction 1-3 time, each 1-4 hour, merge extractive liquid, filtered, filtrate recycling ethanol is not to there being the alcohol flavor, medicinal residues are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati add 4-8 times of water gaging and extract volatile oil, collects volatile oil, device is collected in addition, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, Poria powder are broken into fine powder;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (1), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried oil back residue and aqueous solution merges in the step (2), add 7-10 times of water gaging, heating decocts 1-3 time, each 1-3 hour, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (1), be condensed into clear paste, drying is pulverized, and is standby;
The dried cream powder of step (4) gained comminuted powder, step (3) gained volatile oil and step (5) gained constitutes the active component of this Chinese medicine composition jointly.
The dosage form of medicine of the present invention is capsule, tablet, powder, oral liquid, soft capsule, pill, tincture, syrup, suppository, gel, spray or injection.
The preparation method of capsule wherein, form by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati, united extraction volatile oil is carried the oil time and is no less than 8 hours, volatile oil device is in addition collected, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli two flavor animal drugs, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, the sterilization back is standby;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried oil back residue and aqueous solution merges in the step (3), add 9 times of water gagings, heating decocts 2 times, each 2 hours, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying is pulverized, and is standby;
Step (5) gained dried cream powder is added suitable acceptable accessories granulates;
(6), gained volatile oil in the step (3) is sprayed in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing, with the granule mixing of gained in the step (5), airtight half an hour, promptly encapsulated.
Other dosage forms of medicine of the present invention are in proportion after the weighting raw materials, adopt conventional preparation method preparation, for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record makes the acceptable regular dosage form of pharmaceutics.
For above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
Medicine composite for curing of the present invention makes the spleen renal function vigorous with tonifying speen and tonifying kidney Zhi Qiben, the merit that performance " is supported just long-pending from removing "; Its mark of ruling by law of being aided with silt detoxifcation, resolving mass and removing the obstruction of the collateral, thereby hot detoxicatingization, the ruton stasis of blood is gone.
Pharmaceutical composition of the present invention has the effect of supplementing QI and nourishing YIN, strengthening spleen, tonifying kidney, resolving mass and removing the obstruction of the collateral, and clinical experiment confirms treatment gastric cancer, determined curative effect.Compatibility of the present invention is reasonable, and is simple, is pure Chinese medicinal preparation, and untoward reaction is little, but the patients life-time service.
The specific embodiment
Embodiment 1:
The crude drug prescription is:
Radix Astragali 250g Fructus Ligustri Lucidi 200g Radix Ginseng 65g Ganoderma 65g Rhizoma Curcumae 132g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 64g Herba Scutellariae Barbatae 128g Herb Gynostemmae Pentaphylli 256g Poria 65g Endothelium Corneum Gigeriae Galli 30g
Herba Duchesneae Indicae 128g Herba Solani Lyrati 128g Herba Artemisiae Scopariae 128g Radix Cynanchi Paniculati 128g
Herba Hedyotidis Diffusae 128g Eupolyphaga Seu Steleophaga 20g
Preparation method is:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae (stir-fry), Radix Cynanchi Paniculati, united extraction volatile oil is carried the 8 hours time of oil, volatile oil device is in addition collected, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, in 3KGY
60Standby after the CO-r radiation sterilization;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried behind the oil in the step (3) residue and aqueous solution merge, and adds 9 times of water gagings, heating decocts 2 times, each 2 hours, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying is pulverized, and is standby;
(6), step (5) gained dried cream powder is added starch 134 grams, use 85% alcohol granulation;
(7), with gained volatile oil 85% dissolve with ethanol in the step (3), spray in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing with the granule mixing of the middle gained of step (6), airtight half an hour, is packed 1000 capsules into promptly.
Embodiment 2:
The crude drug prescription is:
Radix Astragali 360g Fructus Ligustri Lucidi 100g Radix Ginseng 95g Ganoderma 30g Rhizoma Curcumae 195g
The Rhizoma Atractylodis Macrocephalae (stir-fry) 30g Herba Scutellariae Barbatae 195g Herb Gynostemmae Pentaphylli 120g Poria 95g Endothelium Corneum Gigeriae Galli 15g
Herba Duchesneae Indicae 195g Herba Solani Lyrati 65g Herba Artemisiae Scopariae 195g Radix Cynanchi Paniculati 65g
Eupolyphaga Seu Steleophaga 30g Herba Hedyotidis Diffusae 65g
Preparation method is:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 6 times of amount 90% alcohol reflux 4 hours, extracting solution reclaims ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae (stir-fry), Radix Cynanchi Paniculati merge, and adds 4 times of water gagings and extract volatile oil, carries the 10 hours time of oil, volatile oil device is in addition collected, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, in 3KGY
60Standby after the CO-r radiation sterilization;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried behind the oil in the step (3) residue and aqueous solution merge, add 7 times of water gagings, heating decocts 3 times, 1 hour for the first time, 2 hours for the second time, 3 hours for the third time, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying is pulverized, and is standby;
(6), step (5) gained dried cream powder is added starch 134 grams, use 78% alcohol granulation;
(7), with gained volatile oil 85% dissolve with ethanol in the step (3), spray in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing, with the granule mixing of the middle gained of step (6), formulation method is made 1000 tablets of tablets routinely.
Embodiment 3:
The crude drug prescription is:
Radix Astragali 120g Fructus Ligustri Lucidi 300g Radix Ginseng 30g Ganoderma 95g Rhizoma Curcumae 65g
Rhizoma Atractylodis Macrocephalae 90g Herba Scutellariae Barbatae 65g Herb Gynostemmae Pentaphylli 360g Poria 30g Endothelium Corneum Gigeriae Galli 45g
Herba Duchesneae Indicae 65g Herba Solani Lyrati 195g Herba Artemisiae Scopariae 65g Radix Cynanchi Paniculati 195g
Eupolyphaga Seu Steleophaga 10g Herba Hedyotidis Diffusae 195g
Preparation method is:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 10 times of amount 50% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati merge, and adds 10 times of water gagings and extract volatile oil, carries the 6 hours time of oil, volatile oil device collection in addition, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, in 3KGY
60Standby after the CO-r radiation sterilization;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), reach residue and the aqueous solution that gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried behind the oil in the step (3) and merge, add 10 times of water gagings, heating decocted 3 hours, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying, pulverize, standby;
(6), with gained volatile oil 80% dissolve with ethanol in the step (3), spray in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing, with the dried cream powder of the middle gained of step (5), formulation method is made 1000 ball pills routinely.
For confirming the curative effect of medicine of the present invention in treatment gastric cancer, use the capsule (to call medicine of the present invention in the following text) that makes by embodiment 1, carried out following clinical experimental study:
Experimental example 1:
The clinical observation on the therapeutic effect of medicine composite for curing gastric cancer of the present invention
1. data and method
1.1 clinical data
107 routine patients with gastric cancer, all be selected from Hebei Yi Ling hospital, all through pathological examination, clarify a diagnosis and be gastric cancer (relevant criterion that diagnostic criteria is formulated with reference to the gastric cancer cooperative groups), age 53-75 year, estimate life cycle greater than 6 months, be associated with except the serious primary disease person such as cardiovascular, liver, kidney and hemopoietic system.Wherein 58 examples are organized in treatment, comprise, male 42 examples, and women 16 examples, men and women's ratio is 2.63: 1; Age 53-75 year, 63.2 years old mean age; Adenocarcinoma 43 examples, mucinous adenocarcinoma 11 examples, seal army cell carcinoma 4 examples; By international TNM by stages, II phases 6 example, III phases 36 example, IV phases 16 example; Metastasis site: lung 26 examples, liver 29 examples, lymphonodi coeliaci 45 examples, pelvic cavity 8 examples, supraclavicular lymph nodes 39 examples, brain 1 example.Two are shifted 11 examples with the upper part.Matched group 49 examples comprise, male 36 examples, and women 13 examples, men and women's ratio is 2.77: 1; Age 53-65 year, 59.8 years old mean age; Adenocarcinoma 35 examples, mucinous adenocarcinoma 9 examples, seal army cell carcinoma 5 examples; By international TNM by stages, II phases 12 example, III phases 28 example, IV phases 9 example; Metastasis site: lung 21 examples, liver 28 examples, lymphonodi coeliaci 33 examples, pelvic cavity 3 examples, supraclavicular lymph nodes 39 examples, brain 3 examples.Two are shifted 13 examples with the upper part.Two groups of sexes, age, histological type and transfer case credit are by statistics analysed there was no significant difference (p＞0.05), have comparability.
1.2 Therapeutic Method
Matched group uses chemotherapy regimen: oxaliplatin 130mg/m2 goes into quiet 2h of liquid (the 1st day), and 5-fluorouracil 400mg/m2 went into quiet of liquid 1-5 days; Calcium folinate 0.2g went into quiet of liquid 1-5 days.Around every is one-period, six cycles of logotype.
The treatment group adds medicine of the present invention on the matched group basis: each 4, every day 3 times is oral, takes continuously 6 months.
1.3 therapeutic evaluation
1.3.1 doing well,improving evaluation
Observe gastralgia, feeling of fullness, loss of appetite, feel sick, vomiting, hematemesis, melena, weak, become thin, symptoms such as picture of the tongue, pulse condition, by light, in, weigh three grades and count 1,2,3 fen respectively, do not have and then count 0 fen, the statistics total mark changes situation before and after the treatment, divide level Four, (1) clinical recovery: clinical symptoms all disappears.(2) produce effects: cardinal symptom (gastral cavilty portion pain, feeling of fullness) is basic to disappear, the symptom total mark reduce 2/3 or more than.(3) effective: cardinal symptom (gastral cavilty portion pain, feeling of fullness) takes a turn for the better, the symptom total mark reduce 1/3 or more than.(4) invalid: the symptom total mark reduces less than 1/3, even total mark increases.Clinical total effective rate is with recovery from illness+produce effects+effectively calculating.
1.3.2 life quality evaluation
Adopt the Ka Shi point system, (1) takes a turn for the better: Karnofsky scoring 〉=10 minutes, (2) are stable: the Karnofsky scoring increased or reduces in 10 minutes, (3) progress: the Karnofsky scoring reduces 〉=10 fens.Clinical total effective rate is with improvement+stability Calculation.
1.3.3 body weight change evaluation
(1) take a turn for the better, weight increase＞2 kilogram, (2) are stable, weight increase or minimizing≤2 kilogram, (3) progress is lost weight＞2 kilograms.Clinical total effective rate is with improvement+stability Calculation.
1.3.4 cancer changes evaluation under the mirror
Press the recent evaluation criteria judgement of the solid tumor curative effect that WHO formulates, divide level Four, (1) alleviates (CR) fully, visible cancer complete obiteration; (2) part is alleviated (PR), and lump dwindles more than 50%, does not have the increase of new focus appearance or any focus; (3) no change (NC): lump dwindles and is no more than 50% or increase and to be no more than 25%; (4) progress (PD): one or more focuses increase above 25%, or new focus occurs.Clinical total effective rate is with alleviation+part alleviation+no change calculating fully.
1.3.5 the serum granulocyte is observed
Two groups of patients all carry out routine blood test and detect before and after treatment, mainly observe leukocyte, hemoglobin, erythrocyte situation, do statistical analysis.
1.3.6 statistical method
Measurement data adopts the T check, and enumeration data adopts raddit to analyze.
2 results
2.1 two groups of patient's doing well,improvings compare (seeing Table 1):
Table 1 liang group patient doing well,improving relatively
Two groups are compared P＜0.05, and the treatment group significantly is better than matched group, and patient's clinical symptoms is obviously improved, and statistical significance is arranged.
2.2 two groups of patient's life qualities compare (seeing Table 2):
Table 2 liang group patient life quality relatively
P＜0.05, the treatment group significantly is better than matched group, and patients ' life quality obviously improves, and statistical significance is arranged.
2.3 two groups of weight in patients change relatively (seeing Table 3):
Table 3 a liang group weight in patients changes relatively
P＜0.05, the treatment group significantly is better than matched group, and weight in patients significantly increases, and statistical significance is arranged.
2.4 the comparison (seeing Table 4) that cancer changes under two groups of patient's mirrors:
The comparison that cancer changes under the table 4 liang group patient mirror
P＜0.05, the treatment group significantly is better than matched group, and cancer obviously dwindles under patient's mirror, and statistical significance is arranged.
2.5 routine blood test changes (seeing Table 5):
Table 5 routine blood test changes
Treatment group treatment back numeration of leukocyte obviously improves (P＜0.05) before the treatment, and matched group then reduces (P＜0.05) before the treatment, and treatment back treatment group is compared with matched group to learn by statistics to handle significant difference (P＜0.05), and statistical significance is all arranged.
3 conclusions
Above clinical research result shows, Chinese medicine composition of the present invention can human body immunity improving power, and gastric cancer is effectively treated in prevention and repair the toxic and side effects of chemotherapy.
Experimental example 2:
Pharmaceutical composition of the present invention is to the Clinical detection of patients with gastric cancer t lymphocyte subset group and natural killer cell activity
1. data and method
1.1 clinical data
Whole 127 routine patients with gastric cancer, be selected from Hebei Yi Ling hospital, all through pathological examination, clarify a diagnosis and be gastric cancer (relevant criterion that diagnostic criteria is formulated with reference to the gastric cancer cooperative groups), age 53-65 year, estimate life cycle greater than 6 months, be associated with except the serious primary disease person such as cardiovascular, liver, kidney and hemopoietic system.Wherein 69 examples are organized in treatment, comprise, male 47 examples, and women 22 examples, men and women's ratio is 2.14: 1; Age 53-68 year, 61.3 years old mean age; Adenocarcinoma 49 examples, mucinous adenocarcinoma 16 examples, seal army cell carcinoma 4 examples; By international TNM by stages, II phases 6 example, III phases 47 example, IV phases 16 example.Matched group 58 examples comprise, male 43 examples, and women 15 examples, men and women's ratio is 2.87: 1; Age 53-65 year, 59.8 years old mean age; Adenocarcinoma 46 examples, mucinous adenocarcinoma 9 examples, seal army cell carcinoma 3 examples; By international TNM by stages, II phases 12 example, III phases 37 example, IV phases 9 example.Two groups of sexes, age, histological type and transfer case credit are by statistics analysed there was no significant difference (p＞0.05), have comparability.
1.2 Therapeutic Method
Matched group: oxaliplatin 130mg/m2 goes into quiet 2h of liquid (the 1st day), and 5-fluorouracil 400mg/m2 went into quiet of liquid 1-5 days; Calcium folinate 0.2g went into quiet of liquid 1-5 days.Around every is one-period, six cycles of logotype.
The treatment group: add medicine of the present invention on the matched group basis, each 4, every day 3 times is oral, takes continuously 6 months.
1.3 observational technique
Two groups of patients all take a blood sample before and after treatment, carry out the active detection of t lymphocyte subset group and natural killer cell (NK).Carry out routine blood test, hepatic and renal function, electrocardiogram safety detection simultaneously.
1.4 statistical method adopts SAS software, the T check
2 results
2.1T lymphocyte and subgroup thereof change
Treatment group treatment back CD4, CD4/CD8 obviously improve (P＜0.05) before the treatment, and the matched group These parameters then obviously reduces (P＜0.05); Treatment back treatment group is compared with matched group, and learning by statistics to handle has significant difference (P＜0.05), illustrates that medicine of the present invention can significantly strengthen cancer patient's t lymphocyte subset group's activity, improves its immunne response ability to body, human body immunity improving power.See Table 6.
The comparison that the t lymphocyte subset group changes before and after the table 6 liang group patient treatment
Annotate: with compare * P＜0.05 before the group internal therapy; With compare #P＜0.05 after the treatment group treatment
2.2 natural killer cell (NK cell) activity change
Treatment group treatment back NK cytoactive obviously improves (P＜0.05) before the treatment, and matched group then reduces (P＜0.05) before the treatment, and treatment back treatment group is compared with matched group to learn by statistics to handle significant difference (P＜0.05).Illustrate that medicine of the present invention can significantly strengthen cancer patient NK cell activity, improve its immune surveillance function, enhancing body antineoplastic ability.See Table 7.
The comparison that natural killer cell changes before and after the table 7 liang group patient treatment
Annotate: with compare * P＜0.05 before the group internal therapy; With compare #P＜0.05 after the treatment group treatment
3 conclusions
Above clinical research result shows that Chinese medicine composition of the present invention can significantly strengthen the activity of patients with gastric cancer t lymphocyte subset group and natural killer cell, effectively treats gastric cancer.
Experimental example 3:
Pharmaceutical composition of the present invention is to the clinical observation of patients with gastric cancer cancer proliferating cell nuclear antigen and saltant P53 protein expression
1. data and method
1.1 clinical data
Whole 110 routine patients with gastric cancer, be selected from Hebei Yi Ling hospital, all through pathological examination, clarify a diagnosis and be gastric cancer (relevant criterion that diagnostic criteria is formulated with reference to the gastric cancer cooperative groups), age 53-66 year, estimate life cycle greater than 6 months, be associated with except the serious primary disease person such as cardiovascular, liver, kidney and hemopoietic system.Wherein 58 examples are organized in treatment, comprise, male 41 examples, and women 17 examples, men and women's ratio is 2.41: 1; Age 53-66 year, 60.8 years old mean age; Adenocarcinoma 41 examples, mucinous adenocarcinoma 16 examples, seal army cell carcinoma 1 example; By international TNM by stages, II phases 6 example, III phases 41 example, IV phases 11 example.Matched group 52 examples comprise, male 37 examples, and women 15 examples, men and women's ratio is 2.47: 1; Age 54-65 year, 59.7 years old mean age; Adenocarcinoma 40 examples, mucinous adenocarcinoma 11 examples, seal army cell carcinoma 1 example; By international TNM by stages, II phases 4 example, III phases 43 example, IV phases 5 example.Two groups of sexes, age, histological type and transfer case credit are by statistics analysed there was no significant difference (p＞0.05), have comparability.
1.2 Therapeutic Method
Matched group: oxaliplatin 130mg/m2 goes into quiet 2h of liquid (the 1st day), and 5-fluorouracil 400mg/m2 went into quiet of liquid 1-5 days; Calcium folinate 0.2g went into quiet of liquid 1-5 days.Around every is one-period, six cycles of logotype.
The treatment group: add medicine of the present invention on the matched group basis, each 4, every day 3 times is oral, takes continuously 6 months.
1.3 observational technique
Two groups of patients all get the cancer tissue in treatment front and back gastroscope, and specimen is through 10% formalin fixed, and routine is dewatered, paraffin Bao Li, and 4 μ m serial section adopt immunohistochemistry technique S-P method.Guiding step by the test kit description carries out.Test kit is Beijing Zhong Shan Bioisystech Co., Ltd product.
1.4 decision method as a result
With made section under the optical microscope low power lens, observe PCNA and p53 protein expression, present the clear and definite brown yellow granule shape positive cell that dyes with nucleus, under low power lens, select evenly earlier and develop the color to contrast the visual field clearly, use the high power lens shared number of counting positive cell in 1000 cells in proper order again instead, with percentage calculation, with
Expression.
1.5 statistical method adopts SAS software, the T check
2 results
PCNA and the reaction of p53 protein immunization are confined in the nucleus, and nucleus is dyed clear and definite pale brown color, and among the whole 110 routine patients, the positive expression rate of PCNA is 97.27%, and the proteic positive expression rate of P53 is 85.45%.High power lens is counting down, with percentage calculation, credit is analysed by statistics, treatment group PCNA and P53, compare obvious reduction after the treatment with before the treatment, statistical significance is arranged, compare decline to some extent after the two treatment of matched group with before the treatment, but the two has compared marked difference after two groups of treatments, the treatment group is better than matched group, clinical have a statistical significance, illustrates that medicine of the present invention can effectively suppress the expression of PCNA and P53, plays the therapeutical effect of cancer-resisting.See Table 8:
Expression before and after table 8PCNA and the P53 protein for treatment in stomach organization
Annotate: with compare * P＜0.05 before the group internal therapy; With compare #P＜0.05 after the treatment group treatment
3 conclusions
Above clinical research result shows that Chinese medicine composition of the present invention can significantly suppress patients with gastric cancer proliferating cell nuclear antigen and the proteic expression of saltant P53, effectively treats gastric cancer.
Comprehensive above all clinical trials, show that medicine of the present invention can significantly improve the immunity of organisms of patients with gastric cancer, strengthen the activity of t lymphocyte subset group and natural killer cell, suppress cancer proliferating cell nuclear antigen and the proteic expression of saltant P53, can effectively treat gastric cancer.
Claims (10)
1. the Chinese medicine composition application in preparation treatment gastric cancer medicine is characterized in that being that the crude drug of following weight portion ratio is made:
Radix Astragali 120-360 Fructus Ligustri Lucidi 100-300 Radix Ginseng 30-95 Ganoderma 30-95
Rhizoma Curcumae 65-195 Rhizoma Atractylodis Macrocephalae 30-90 Herba Scutellariae Barbatae 65-195 Herb Gynostemmae Pentaphylli 120-360
Poria 30-95 Endothelium Corneum Gigeriae Galli 15-45 Herba Duchesneae Indicae 65-195 Herba Solani Lyrati 65-195
Herba Artemisiae Scopariae 65-195 Radix Cynanchi Paniculati 65-195 Eupolyphaga Seu Steleophaga 10-30 Herba Hedyotidis Diffusae 65-195.
2. application according to claim 1 is characterized in that being made by following bulk drugs:
The Radix Astragali 120 Fructus Ligustri Lucidi 300 Radix Ginsengs 30 Ganodermas 95 Rhizoma Curcumae 65 Rhizoma Atractylodis Macrocephalaes 90
Herba Scutellariae Barbatae 65 Herb Gynostemmae Pentaphylli 360 Poria 30 Endothelium Corneum Gigeriae Galli 45 Herba Duchesneae Indicaes 65
Herba Solani Lyrati 195 Herba Artemisiae Scopariaes 65 Radix Cynanchi Paniculatis 195 Eupolyphaga Seu Steleophagas 10 Herba Hedyotidis Diffusaes 195.
3. application according to claim 1 is characterized in that being made by following bulk drugs:
The Radix Astragali 360 Fructus Ligustri Lucidi 100 Radix Ginsengs 95 Ganodermas 30 Rhizoma Curcumae 195 Rhizoma Atractylodis Macrocephalaes 30
Herba Scutellariae Barbatae 195 Herb Gynostemmae Pentaphylli 120 Poria 95 Endothelium Corneum Gigeriae Galli 15 Herba Duchesneae Indicaes 195
Herba Solani Lyrati 65 Herba Artemisiae Scopariaes 195 Radix Cynanchi Paniculatis 65 Eupolyphaga Seu Steleophagas 30 Herba Hedyotidis Diffusaes 65.
4. application according to claim 1 is characterized in that being made by following bulk drugs:
The Radix Astragali 250 Fructus Ligustri Lucidi 200 Radix Ginsengs 65 Ganodermas 65 Rhizoma Curcumae 132 Rhizoma Atractylodis Macrocephalaes 64
Herba Scutellariae Barbatae 128 Herb Gynostemmae Pentaphylli 256 Poria 65 Endothelium Corneum Gigeriae Galli 30 Herba Duchesneae Indicaes 128
Herba Solani Lyrati 128 Herba Artemisiae Scopariaes 128 Radix Cynanchi Paniculatis 128 Herba Hedyotidis Diffusaes 128 Eupolyphaga Seu Steleophagas 20.
5. according to each described application of claim 1-4, it is characterized in that the described Rhizoma Atractylodis Macrocephalae is a Rhizoma Atractylodis Macrocephalae (parched).
6. according to each described application of claim 1-4, it is characterized in that the active component of described Chinese medicine composition is made by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Fructus Ligustri Lucidi, people participate in 6-10 and doubly measure the 50-90% ethanol extraction 1-3 time, each 1-4 hour, merge extractive liquid, filtered, filtrate recycling ethanol is not to there being the alcohol flavor, medicinal residues are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati add 4-8 times of water gaging and extract volatile oil, collects volatile oil, device is collected in addition, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli, Poria powder are broken into fine powder;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (1), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried oil back residue and aqueous solution merges in the step (2), add 7-10 times of water gaging, heating decocts 1-3 time, each 1-3 hour, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (1), be condensed into clear paste, drying is pulverized, and is standby;
The dried cream powder of step (4) gained comminuted powder, step (3) gained volatile oil and step (5) gained constitutes the active component of this Chinese medicine composition jointly.
7. according to each described application of claim 1-4, it is characterized in that described Chinese medicinal composition preparation dosage form is capsule, tablet, powder, oral liquid, soft capsule, pill, tincture, syrup, suppository, gel, spray or injection.
8. according to the preparation method of the described medicine capsule of claim 7, it is characterized in that forming by following steps:
(1), take by weighing Chinese crude drug, clean according to the crude drug part by weight;
(2), Radix Ginseng, Fructus Ligustri Lucidi, add 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor, Radix Ginseng, Fructus Ligustri Lucidi residue are standby;
(3), Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati, united extraction volatile oil is carried the oil time and is no less than 8 hours, volatile oil device is in addition collected, residue and aqueous solution are standby;
(4), Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli two flavor animal drugs, washing, 60 ℃ of oven dry merge with Poria, are ground into 100 order powder, the sterilization back is standby;
(5), the Radix Astragali, Ganoderma, Herba Hedyotidis Diffusae, Herba Scutellariae Barbatae, Herb Gynostemmae Pentaphylli, Herba Duchesneae Indicae, Herba Solani Lyrati, Herba Artemisiae Scopariae, with residue after the alcohol extraction of gained Radix Ginseng, Fructus Ligustri Lucidi in the step (2), and gained Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Cynanchi Paniculati are carried oil back residue and aqueous solution merges in the step (3), add 9 times of water gagings, heating decocts 2 times, each 2 hours, merge decoction liquor, add gained Radix Ginseng, Fructus Ligustri Lucidi alcohol extract in the step (2), be condensed into the clear paste of relative density 1.20-1.25, drying is pulverized, and is standby;
Step (5) gained dried cream powder is added suitable acceptable accessories granulates;
(6), gained volatile oil in the step (3) is sprayed in the fine powder of gained Poria, Eupolyphaga Seu Steleophaga, Endothelium Corneum Gigeriae Galli in the step poly-(4), mixing, with in the step (5) in the granule mixing of gained, airtight half an hour, promptly encapsulated.
9. according to each described application of claim 1-4, it is characterized in that the application of described Chinese medicine composition in the medicine of preparation enhancing patients with gastric cancer t lymphocyte subset group and natural killer cell activity.
10. according to each described application of claim 1-4, it is characterized in that the application of described Chinese medicine composition in the medicine of preparation inhibition patients with gastric cancer cancer proliferating cell nuclear antigen and saltant P53 protein expression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101412123A CN102210836A (en) | 2010-04-08 | 2010-04-08 | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101412123A CN102210836A (en) | 2010-04-08 | 2010-04-08 | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102210836A true CN102210836A (en) | 2011-10-12 |
Family
ID=44742520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101412123A Pending CN102210836A (en) | 2010-04-08 | 2010-04-08 | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102210836A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013071727A1 (en) * | 2011-11-14 | 2013-05-23 | Fan Shenggang | Anti-tumor traditional chinese medical composition |
| CN103417907A (en) * | 2012-05-26 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of traditional Chinese medicine composition in preparation of drug used for inhibiting angiogenesis |
| CN103830662A (en) * | 2012-05-26 | 2014-06-04 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of drug for inhibiting rheumatoid arthritis angiogenesis |
| WO2014176934A1 (en) * | 2013-05-02 | 2014-11-06 | 河北以岭医药研究院有限公司 | Use of traditional chinese medicine composition in preparation of drugs for treating or preventing angiogenesis related diseases |
| CN104324316A (en) * | 2013-07-22 | 2015-02-04 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer |
| CN104825612A (en) * | 2015-05-27 | 2015-08-12 | 苗怡文 | Medicine composition for treating gastritis and method for manufacturing medicine composition |
| CN111228437A (en) * | 2018-11-29 | 2020-06-05 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating fatigue syndrome |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1255181C (en) * | 2004-06-15 | 2006-05-10 | 河北以岭医药研究院有限公司 | Preparation of medicinal composition for nourishing |
-
2010
- 2010-04-08 CN CN2010101412123A patent/CN102210836A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1255181C (en) * | 2004-06-15 | 2006-05-10 | 河北以岭医药研究院有限公司 | Preparation of medicinal composition for nourishing |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013071727A1 (en) * | 2011-11-14 | 2013-05-23 | Fan Shenggang | Anti-tumor traditional chinese medical composition |
| CN103417907A (en) * | 2012-05-26 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of traditional Chinese medicine composition in preparation of drug used for inhibiting angiogenesis |
| CN103830662A (en) * | 2012-05-26 | 2014-06-04 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of drug for inhibiting rheumatoid arthritis angiogenesis |
| CN103830662B (en) * | 2012-05-26 | 2017-09-26 | 石家庄以岭药业股份有限公司 | A kind of application of Chinese medicine composition in treatment medicine for treating rheumatoid arthritis is prepared |
| WO2014176934A1 (en) * | 2013-05-02 | 2014-11-06 | 河北以岭医药研究院有限公司 | Use of traditional chinese medicine composition in preparation of drugs for treating or preventing angiogenesis related diseases |
| CN104324316A (en) * | 2013-07-22 | 2015-02-04 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer |
| CN104825612A (en) * | 2015-05-27 | 2015-08-12 | 苗怡文 | Medicine composition for treating gastritis and method for manufacturing medicine composition |
| CN111228437A (en) * | 2018-11-29 | 2020-06-05 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating fatigue syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102274447B (en) | Medicinal composition for treating diabetes | |
| CN101332284B (en) | Chinese traditional medicine composition for treating ulcerative colitis and its preparation method | |
| CN100408067C (en) | Chinese medicines for stomach pain due to Qi stagnation and its preparing method | |
| CN102210836A (en) | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer | |
| CN101590200A (en) | The application of a kind of Chinese medicine composition in the medicine of preparation treatment tumor | |
| CN102266508B (en) | Chinese medicinal composition for treating drying syndrome and preparation method and application thereof | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN103386078B (en) | A kind of Chinese medicine composition is preparing the application in treating colon cancer drug | |
| CN102813870B (en) | Chinese herbal compound preparation used for treating alcoholism and gout and preparation method and application thereof | |
| CN102727787B (en) | Drug with characteristics of rapid transaminase lowering and live protection | |
| CN101732566B (en) | Traditional Chinese medicine compound preparation for tonifying liver and kidney and strengthening bones and muscles | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN101810671A (en) | Chinese medicinal preparation for treating AIDS and preparation method thereof | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN101579496B (en) | Application of Chinese medicine composition in preparation of medicine for treating atypical hyperplasia of gastric mucosa | |
| CN112717097A (en) | Traditional Chinese medicine composition for treating gastric cancer and preparation method thereof | |
| CN101683421B (en) | Applications of traditional Chinese medicine composition in preparation of medicament for treating repetitive respiratory tract infection | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN102772540B (en) | A kind of medicine for the treatment of metabolism syndrome | |
| CN102847060A (en) | Traditional Chinese medicine composition for treating uterine myoma and preparation method thereof | |
| CN103230552A (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN102600436A (en) | Traditional Chinese medicine compound preparation for treating gastric cancer and preparation method thereof | |
| CN103768454A (en) | Composition for preventing and treating HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) and preparation method thereof | |
| CN101313990A (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN105434533A (en) | Traditional Chinese medicine composition for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20111012 |